PUBLICATIONS AND INTELLECTUAL PROPERTY

The work of NanoSiliCal Devices is based on a strong background of knowledge and skills gained in ten years’ experience, deriving from the results of experimental studies which led to several International Patent Applications and publications in high impact factor international journals,. Thus, our company has the know-how to produce a great variety of systems that could be useful for several therapies, not only cancer, since they can carry a lot of different drugs and, at the same time, they can be linked with different specific targeting molecules.

Publications

Pasqua L, Testa F, Aiello R, Cundari S, Nagy JB. Preparation of bifunctional hybrid mesoporous silica potentially useful for drug targeting. Micropor Mesopor Mat. 2007; 103: 166-73.

Pasqua L, Morelli C., Testa F., Sisci D., Brunelli E., Aiello R., Andò S. and Nagy J.B. (2007). Preparation and cell inclusion of fluorescent folic acid- functionalized mesoporous silica microsphere potentially useful for drug targeting. Stud.Surf. Sci. Catal., Vol. 170, ISSN: 0167-2991

Pasqua L, Cundari S.,. Ceresa C, Cavaletti G. (2009). Recent Development, Applications, and Perspectives of mesoporous Silica Particles in Medicine and Biotechnology. Curr Med Chem vol. 16, p. 3054-3063, ISSN: 0929-8673

Morelli C., Maris P., Sisci D., Perrotta E., Brunelli E., Perrotta I., Panno M.L , Tagarelli A., Versace C., Casula M.F., Testa F.,.Andò S., Nagy J.B. and Pasqua L.; PEG-templated mesoporous silica nanoparticles Exclusively target cancer cells. Nanoscale. 2011; 3: 3198-207.

Ceresa C., Nicolini G., Rigolio R., Bossi M., Pasqua L., Cavaletti G.; Functionalized Silica Nanoparticles: A Possible Strategy to Target Cancer Cells Reducing Peripheral Nervous System Uptake. Curr Med Chem. 2013; 20: 2589-600.

Patent applications

NanoSiliCal Devices owns the following patents:

1. EP2001514B1 – “Preparation of micro or nano systems based on inorganic oxides with controlled porosity for carrying biologically active or activable substances” by Luigi Pasqua, Flaviano Testa, Rosario Aiello, Umberto Maione. This patent, which claims the overall technology, was granted on 31/05/2017 and is now owned by NanoSiliCal Devices. In this patent any kind of drug (also radionuclide for localized radiotherapy) and receptor-specific ligands are claimed. The designated contracting states for EP2001514B1 are: Austria, Belgium, Switzerland, Cyprus, Czech Republic, Germany, Denmark, Estonia, Spain, Finland, France, Great Britain, Greece, Hungary, Ireland, Iceland, Italy, Liechtenstein, Lithuania, Luxembourg, Latvia, Monaco, Holland, Poland, Portugal, Romania, Sweden, Slovenia, Slovak Republic and Turkey.

2. PCT/IT2016/000111 – “Bortezomib-based delivery system” by Pasqua L., Morelli C., Leggio A., Liguori A., Andò S., now owned by NanoSiliCal Devices, Publication number, WO2016174693 A1. Application number PCT/IT2016/000111.

On April 2016, NanoSiliCal Devices applied for the extension of the same PCT to:

– Canada – Application Number: 2,985,311; Approval number: 14910/00001.

– European Patent – Application Number: 16733715.3; Reference Number: EPI-13871.

– China – Application Number: 201680024374.4; Recognition number: 2017110800706640.

– Russia – Application Number: 2017135265; Approval number: 061612.

– USA – Application Number: 15 / 570.254; Attorney docket number: GRT2818-327.

– India – Presentation concerning the code: PCT / IT2016 / 00011.

– Brazil – Application number: IT2016 / 000111.

– Australia – Application number 2016255738; Reference number 35273822 / PDB / KWW.

NanoSiliCal Devices innovative technology can rapidly generate the data needed to extend the life cycle of an already established drug, through a new Intellectual Properties (IP) obtained for the complex with the MSN drug delivery systems.